pirfenidone has been researched along with Elephantiasis Neuromatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babovic-Vuksanovic, D; Balis, FM; Blaney, SM; Cohen, B; Dombi, E; Fox, E; Goldman, S; Goodspeed, W; Goodwin, A; Kieran, MW; King, A; Martin, S; Packer, RJ; Patronas, N; Solomon, J; Steinberg, SM; Widemann, BC; Wolters, PL | 1 |
| Babovic-Vuksanovic, D; Beck, H; Dombi, E; Fox, E; Gillespie, A; MacDonald, T; O'Neill, BP; Packer, RJ; Toledo-Tamula, MA; Widemann, BC; Wolters, PL | 1 |
2 trial(s) available for pirfenidone and Elephantiasis Neuromatosis
| Article | Year |
|---|---|
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Staging; Neurofibroma, Plexiform; Neurofibromatosis 1; Prognosis; Pyridones; Quality of Life; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Neurofibroma, Plexiform; Neurofibromatosis 1; Pyridones; Quality of Life; Therapeutic Equivalency | 2007 |